

AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG

Cat. No.: HY-P3637
CAS No.: 2640019-27-6
Sequence Shortening: AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG
Target: Others
Pathway: Others
Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG

BIOLOGICAL ACTIVITY

Description	AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG promotes bone-ossification. AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG can be used in the research of diseases or disorders related to osteogenic defects or bone mineral density (BMD) decreasing, such as osteoporosis ^[1] .	
In Vivo	AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG (2.5 and 5 µg/kg, s.c.) promotes ossification in Ovariectomy (OVX)-induced osteoporosis rats ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Ovariectomy (OVX)-induced osteoporosis rats ^[1]
	Dosage:	2.5 µg/kg, 5 µg/kg
	Administration:	Subcutaneous injection (s.c.)
	Result:	Increased bone mineral density in thigh bone and lumbar vertebra.

REFERENCES

[1]. Fu Guoqin, et al. Active polypeptide compound. Patent. WO2021068550.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA